Australia markets close in 3 hours 7 minutes

Recce Pharmaceuticals Ltd (RCE.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.4600+0.0050 (+1.10%)
As of 11:00AM AEDT. Market open.
Full screen
Previous close0.4550
Open0.4500
Bid0.4500 x 55200
Ask0.4600 x 1644700
Day's range0.4500 - 0.4600
52-week range0.4150 - 0.7772
Volume123,117
Avg. volume91,925
Market cap93.703M
Beta (5Y monthly)1.28
PE ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings date27 Feb 2024 - 01 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections

    Independent Safety Committee unanimously agrees that the Phase I/II trial is safe, well tolerated, and fit for expanded accessStudy achieving primary endpoints of safety, tolerability, and efficacy by resolving/curing bacterial infections in patients with diabetic foot ulcersRECCE® 327 dosed daily or every second day for 14 days is considered to be safe and well-toleratedAdditional clinical sites to be launched in Australia, and additional clinical trials will be launched internationally in diab

  • GlobeNewswire

    Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program

    Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana BiotechnologiesMoU aims to facilitate late-stage clinical trials in Indonesia, supporting the Indonesian Government’s access to novel infectious disease medicinesOpportunity to access 10 ASEAN member states1 covering a population of 670 million inhabitantsPatient populations readily available focused on significant unmet medical needs particular to the regionSignificant bilateral initiative supported by the Aus

  • GlobeNewswire

    Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections

    Phase I/II trial assessing the safety and efficacy of RECCE® 327 (R327), a broad-spectrum anti-infective as a topical treatment, met all primary endpointsR327 was well-tolerated in all patients, resolving mild skin and soft tissue diabetic foot infections (DFI), including multidrug-resistant Gram-positive and Gram-negative pathogensData supports imminent domestic and international site expansion SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q),